A Phase 3 Clinical Study of KHK4827

Kyowa Kirin

Status and phase

Completed

Phase 3

Conditions

Psoriasis

Treatments

Drug: KHK4827

Study type

Interventional

Funder types

Industry

Identifiers

NCT01782924

4827-003

Details and patient eligibility

About

This study is designed to evaluate safety and efficacy of long-term exposure of KHK4827 in subjects with moderate to severe plaque psoriasis who have completed the preceding Study 4827-002.

Enrollment

145 patients

Sex

All

Ages

20 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject has voluntarily signed the written informed consent form to participate in this study
Subject has completed the week 12 evaluation of Study 4827-002

Exclusion criteria

Subject has had a serious infection, defined as requiring systemic treatment with antibiotics or antivirals (excluding oral administration)
Subject has been judged to be ineligible for participation in the study by the investigators/subinvestigators